Related Experiment Video
Updated: Jun 6, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Relationship between cardiac autonomic function and sustained ventricular tachyarrhythmias in patients with an
Irma Battipaglia1, Lucy Barone, Luca Mariani
1Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, 00168 Rome, Italy.
Insights
Heart rate variability (HRV) analysis may improve risk stratification for sudden cardiac death in dilated cardiomyopathy (DCM) patients with low ejection fraction receiving implantable cardioverter defibrillators (ICDs). Depressed HRV indices correlate with appropriate ICD shocks, aiding in therapy decisions.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Low left ventricular ejection fraction (LVEF) is a primary indication for implantable cardioverter defibrillators (ICDs) in dilated cardiomyopathy (DCM) for sudden cardiac death prevention.
- A minority of DCM patients with ICDs experience device therapy at follow-up, highlighting the need for improved risk stratification.
- Heart rate variability (HRV) is a potential non-invasive marker for autonomic nervous system function and cardiac risk.
Purpose of the Study:
- To investigate if heart rate variability (HRV) analysis can enhance risk stratification in patients with dilated cardiomyopathy (DCM) who have received an implantable cardioverter defibrillator (ICD).
- To determine the association between HRV parameters and appropriate ICD shocks in DCM patients with reduced LVEF.
- To assess the utility of HRV in predicting both recent and long-term ICD therapy.
Main Methods:
- A study cohort of 42 patients with idiopathic or ischemic DCM and LVEF <40% who had previously undergone ICD implantation was analyzed.
- Patients underwent 24-hour Holter monitoring with HRV assessment over a 2-hour period during stable sinus rhythm.
- Left ventricular ejection fraction (LVEF), C-reactive protein, and NT-proBNP levels were measured. Appropriate ICD shocks (primary endpoint: last 6 months; secondary endpoint: since implant) were recorded.
Main Results:
- Seventeen percent of patients experienced appropriate ICD shocks in the 6 months preceding the study; no differences were found in LVEF or biomarker levels between shocked and non-shocked groups.
- Significantly depressed HRV parameters, including time-domain standard deviations of RR intervals and frequency-domain LF amplitude, were observed in patients with recent ICD shocks (P=0.02 for both).
- Very low-frequency (VLF) amplitude was the sole HRV parameter significantly associated with ICD shocks recorded since device implantation (P=0.049).
Conclusions:
- In DCM patients with reduced LVEF and ICDs, depressed HRV indices are significantly associated with appropriate ICD shocks, particularly within the preceding 6 months.
- VLF amplitude specifically showed association with long-term ICD shocks since implantation.
- Comprehensive HRV analysis holds promise for improving risk stratification and guiding ICD indications in DCM patients at risk of life-threatening ventricular arrhythmias.
Aims:
Low left ventricular ejection fraction (LVEF) is the main indication of implantable cardioverter defibrillators (ICD) in patients with dilated cardiomyopathy (DCM) for the primary prevention of sudden cardiac death, but ICD therapy at follow-up occurs in a minority of patients. We investigated whether heart rate variability (HRV) may improve risk stratification in DCM patients.
Methods And Results:
We studied 42 patients (age 67.3 ± 3.5; 37 males) who had undergone ICD implant for either idiopathic or ischaemic DCM (LVEF <40%) 34.6 ± 19.7 months prior to the study (range 6-84). Patients underwent 24 h electrocardiographic Holter monitoring, and HRV was assessed over 2 hours in the afternoon showing stable sinus rhythm. Left ventricular ejection fraction was measured by two-dimensional echocardiography. The serum levels of C-reactive protein and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were also obtained. The primary endpoint was the occurrence of appropriate ICD shocks in the 6 months preceding the study. The occurrence of appropriate ICD discharge from ICD implant was considered as a secondary endpoint. In the last 6 months, appropriate ICD shocks had occurred in seven patients (17%). There were no differences between patients with and without ICD shocks in clinical variables, as well as in LVEF and in C-reactive protein and NT-proBNP serum levels. In contrast, most HRV parameters were significantly depressed in patients with, compared with those without, ICD shocks; the most significant difference was shown for the average of the standard deviations of RR intervals in all consecutive 5 min segments (n ¼ 12) within the 2 h (26.7 ± 9 vs. 39.7 ± 14 ms; P = 0.02) in the time domain and for LF amplitude (8.4 ± 3 vs. 14.8 ± 7 ms; P = 0.02) in the frequency domain. Implantable cardioverter defibrillator discharge had occurred in 11 patients (26%) since ICD implant (average 35 months). No clinical or laboratory variable showed significant differences between patients with or without ICD discharge, except very low-frequency (VLF) amplitude (23.8 ± 7 vs. 30.8 ± 10.6 ms, respectively; P = 0.049).
Conclusion:
In ICD patients with reduced LVEF, several depressed HRV indices were significantly associated with appropriate ICD shocks in the previous 6 months, and VLF amplitude was the only variable significantly associated with ICD shocks recorded since ICD implant. These data suggest that full HRV analysis might be helpful for improving risk stratification for life-threatening ventricular arrhythmias and ICD indication in patients with DCM.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiomyopathy V: Interprofessional Care
Dysrhythmias VI: Management of Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
